103030-70-2

Usage

Uses

Used in Scientific Research:
5-Methoxy-1,2,3,4-tetrahydro-isoquinoline is used as a research compound for studying neurochemistry and pharmacology. Its presence in scientific research aids in understanding the interactions and effects of 5-METHOXY-1,2,3,4-TETRAHYDRO-ISOQUINOLINE on the nervous system and potential therapeutic applications.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 5-Methoxy-1,2,3,4-tetrahydro-isoquinoline is used as a starting material or intermediate in the synthesis of various drugs. Its unique structure and properties make it a valuable component in the development of new medications, particularly those targeting neurological disorders and conditions.

Upstream product

• 90806-58-9 5-methoxyisoquinoline 
• 29969-46-8 2-formyl-1,2,3,4-tetrahydro-5-methoxyisoquinoline 
• 50-00-0 formaldehyd 
• 2045-79-6 o-methoxy-2-phenylethylamine 
• 258882-54-1 N-(methoxycarbonyl)-2-(2-methoxyphenyl)ethylamine 
• 129075-49-6 3,4-dihydro-5-methoxy-1(2H)-isoquinolinone 
• 2439-04-5 5-hydroxyisoquinoline 
• 39964-84-6 (3-Methoxy-benzylidenamino)-acetaldehyd-dimethylacetal 
• 212184-83-3 5-Methoxy-4-phenylsulfanyl-3,4-dihydro-1H-isoquinoline-2-carbaldehyde 
• 212184-76-4 N-(2-Benzenesulfinyl-ethyl)-N-(3-methoxy-benzyl)-formamide 
• 212184-93-5 N-(3-Methoxy-benzyl)-N-(2-phenylsulfanyl-ethyl)-formamide 
• 212184-89-9 (3-Methoxy-benzyl)-(2-phenylsulfanyl-ethyl)-amine 
• 591-31-1 3-methoxy-benzaldehyde 
• 53366-27-1 N-(3-methoxybenzyl)aminoacetaldehyde dimethyl acetal 

Downstream Products

• 508236-06-4 5-(3,4-Dimethoxybenzylamino)-2-(2-furyl)-8-(5-methoxy-1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)[1,2,4]triazolo[1,5-c]pyrimidine 
• 860436-56-2 tert-butyl 5-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1394241-52-1 C₁₇H₁₇NO₅S 
• 881686-31-3 N-[(1R,4S,5S,7R)-5-(3-isopropoxyphenyl)-4-methyl-2-(3-phenylpropyl)-2-azabicyclo[3.3.1]non-7-yl]-3-(5-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)propionamide 

Relevant academic research and scientific papers

Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter

The synthesis and structure-activity relationship of a new class of indole derivatives with low-nanomolar affinity for the SERT and high selectivity versus the 5-HT1A receptor were recently reported. Based on their chemical structure, four new indolylpropylamine derivatives which contain atoms to afford future labeling with PET isotopes, were synthesized and evaluated as SERT ligands. The chemistry of these novel derivatives, their biological evaluation, the general method of preparing the precursor indole for labeling, and the C-11 labeling of the most promising indole derivative, are described herein.

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

UREA PEPTOID BORIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USES THEREOF

The present invention provides a urea peptidomimetic boronic compound and pharmaceutical compositions thereof, their preparative methods and uses. The compounds are represented by the following formula (I).

Structure-Based Design and Discovery of New M2 Receptor Agonists

Muscarinic receptor agonists are characterized by apparently strict restraints on their tertiary or quaternary amine and their distance to an ester or related center. On the basis of the active state crystal structure of the muscarinic M2 receptor in complex with iperoxo, we explored potential agonists that lacked the highly conserved functionalities of previously known ligands. Using structure-guided pharmacophore design followed by docking, we found two agonists (compounds 3 and 17), out of 19 docked and synthesized compounds, that fit the receptor well and were predicted to form a hydrogen-bond conserved among known agonists. Structural optimization led to compound 28, which was 4-fold more potent than its parent 3. Fortified by the discovery of this new scaffold, we sought a broader range of chemotypes by docking 2.2 million fragments, which revealed another three micromolar agonists unrelated either to 28 or known muscarinics. Even pockets as tightly defined and as deeply studied as that of the muscarinic reveal opportunities for the structure-based design and the discovery of new chemotypes.

SAR studies of capsazepinoid bronchodilators. Part 1: The importance of the catechol moiety and aspects of the B-ring structure

Capsazepine as well as its derivatives and analogues are general inhibitors of constriction of human small airways. From a systematic variation of the capsazepine structure, divided into four regions, SARs were established. This part concerns the catechol moiety of the A-ring as well as the 2,3,4,5-tetrahydro-1H-2-azepine moiety (the B-ring) of capsazepine. It is revealed that a conformational constrain (as a fused ring) is important and that compounds with a six-membered B-ring (as a 1,2,3,4-tetrahydroisoquinoline) in general are more potent than the corresponding isoindoline, 2,3,4,5-tetrahydro-1H-2-benzazepine and 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives.

Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia

Compounds of formula I, STR1whereinR 1 represents C 1-4 alkoxy optionally substituted by one or more fluorine atoms;R 2 represents H or C 1-6 alkoxy optionally substituted by one or more fluorine atoms;R 3 represents a 5- or 6-membered heterocyclic ring, the ring being optionally substituted;R 4 represents a 4-, 5-, 6-, or 7-membered heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring, the ring system as a whole being optionally substituted;X represents CH or N; andL is absent,or represents a cyclic group of formula Ia, STR2or represents a chain of formula Ib, STR3and pharmaceutically acceptable salts thereof, are useful in therapy, in particular in the treatment of benign prostatic hyperplasia.

Studies towards the next generation of antidepressants. Part 1: Indolylcyclohexylamines as potent serotonin reuptake inhibitors

A series of indolylcyclohexylamines possessing potent and selective serotonin reuptake inhibition is reported. The most interesting compounds proved to have subnanomolar 5-HT transporter activity, and exhibited moderate 5-HT1A affinity.

A synthesis of mono- and dimethoxy-1,2,3,4-tetrahydroisoquinolines via Pummerer reaction: Effects of methoxyl groups on intramolecular cyclization

A synthesis of 1,2,3,4-tetrahydroisoquinolines (TIQs) (23) with one and two methoxyl groups at various positions of the benzene ring was achieved via the intramolecular cyclization of N-(aryl)methyl-2- (phenylsulfinyl)ethylamines (9) using the Pummerer reaction as a key step. The reaction was carried out by using trifluoroacetic anhydride (TFAA) (method A) or TFAA-BF3 · Et2O (method B). The cyclization to 4-SPhTIQs (11) proceeded effectively when the reaction center at the benzene ring was electronically activated by a methoxyl group. In the reaction of the sulfoxide (9e) having two OMe groups at ortho- and para-positions a different cyclization reaction leading to a benzothiazepine (12) was observed, indicating that the high nucleophilicity of the benzene ring caused the unexpected reaction prior to the cyclization to 4-SPhTIQ (11e). The route starting from methoxylated benzaldehydes (5) was proved to provide an efficient and convenient method of TIQ synthesis which should be complementary to the well known Pictet-Spengler method.